DNA strand intertwining with immune cells, symbolizing genetic and immune system connection.

Unlocking the Mystery of CVID: How Genetic Testing Can Improve Diagnosis

Beau Callahan in Health & Wellness October 2026 • 4 min read.

"Whole exome sequencing identifies novel mutations linked to common variable immunodeficiency, paving the way for personalized treatment strategies."

Common variable immunodeficiency (CVID) is a type of primary immunodeficiency disorder (PID). It is characterized by a wide range of symptoms and genetic causes, which can be either monogenic or complex. Recurrent respiratory infections are a common sign, but those affected can also experience autoimmune issues and an increased risk of malignancies.

Due to CVID's heterogeneity, genetic testing, especially whole exome sequencing (WES), is essential for pinpointing potential genetic defects to improve clinical management. WES looks at the protein-coding regions of the genome, offering a route to uncovering mutations that other tests might miss.

This article explores three unusual cases of CVID, each presenting with recurrent respiratory infections alongside varying autoimmune and lymphoproliferative complications. By using WES, researchers aimed to identify the specific mutations driving these conditions, paving the way for more targeted treatments.

AI Search Multiple angles on this topic

Stats & Impact

CVID’s Genetic and Clinical Diversity

Common variable immunodeficiency (CVID) belongs to the primary immunodeficiency disorders (PIDs). The condition shows substantial heterogeneity in both phenotype and genotype. Its causes may be monogenic or complex, making its clinical and genetic impact varied.

Decoding CVID: The Role of Whole Exome Sequencing

DNA strand intertwining with immune cells, symbolizing genetic and immune system connection.

In this study, whole exome sequencing (WES) was performed on three patients with sporadic CVID, each exhibiting unique clinical presentations involving recurrent respiratory infections, autoimmune complications, and lymphoproliferative disorders. The goal was to identify the underlying genetic causes or associated mutations contributing to their conditions.

The process involved a detailed genetic analysis. Key steps included:

Exome Capture: Using the Agilent SureSelect Human All Exon V6 kit, researchers efficiently captured the exome (the protein-coding regions of the genome) from each patient's DNA.
DNA Sequencing: The captured exomes were then sequenced using the Hiseq 4000 platform (Illumina), generating paired-end reads of 150 bp.
Data Analysis: The raw sequencing data was mapped to the human reference genome (UCSC hg19) using the Burrows-Wheeler Aligner (BWA). Subsequent steps involved sorting, marking duplicate reads, and variant calling using SAMtools and Picard Tools.
Variant Annotation: Detected single nucleotide variants (SNVs) and insertions/deletions (indels) were annotated using the ANNOVAR software to predict their potential functional impact.

AI Search Multiple angles on this topic

Latest Research

Why Diagnostic Genetic Testing Matters

A review argues that all patients with common variable immunodeficiency disorders should routinely be offered diagnostic genetic testing. It reports that digenic patients can only be identified by next-generation sequencing (NGS). The review therefore supports sequencing both genes causing CVID-like disorders, including NFKB1 and NFKB2, and genes that may modify disease severity, such as TNFRSF13B/TACI.

Counterpoints

Limits of Evidence From Sporadic Cases

The cited study examined three sporadic CVID cases. These cases were admitted to the Department of Respiratory and Critical Care Medicine at Peking University People’s Hospital. Researchers used whole exome sequencing (WES) to investigate the genetic disorders underlying their phenotypes, but the small number of cases limits how broadly the findings can be generalized.

By employing this comprehensive approach, the study sought to uncover the specific genetic mutations responsible for the diverse manifestations observed in these CVID patients, offering valuable insights into the molecular basis of this complex immunodeficiency.

Precision Diagnosis: The Future of CVID Management

This research underscores the importance of genetic testing, specifically WES, in diagnosing and managing CVID. Identifying specific genetic defects allows for a more precise understanding of the disease, moving beyond symptom management to address the underlying molecular mechanisms.

The identification of novel mutations in genes like LRBA and NFKB1 highlights the ongoing need for genetic investigation in CVID patients. Combining clinical evaluations with genetic diagnoses can significantly improve treatment strategies, especially given the complexity and heterogeneity of CVID.

While the study faced limitations such as the inability to verify the functional effects of identified mutations, it provides a strong foundation for future research. As genetic testing becomes more accessible, it promises to transform CVID diagnosis and management, offering hope for personalized and more effective treatments.

What the genetic findings add to the case descriptions

The reported variants do not all carry the same explanatory weight: the authors linked variants in LRBA and TNFRSF13B to case 1, but said the TNFRSF13B variant alone was insufficient to cause that patient’s CVID phenotype. This illustrates why finding a variant is not by itself proof that it explains the full clinical picture.^[1]

What constrains interpretation of the genetic findings

Most CVID cases still have no identified genetic cause, and the paper estimates monogenic disease accounts for a limited share of cases.^[1]
The authors did not verify the mutations’ functional effects at the expression level, so their biological consequences were not directly established in this study.^[1]
A monoallelic LRBA finding in a patient did not account for her phenotype, limiting how confidently that variant can be treated as causal.^[1]

The three sporadic cases in the paper's own terms

Population	Three sporadic cases of CVID^[2]
Sample size	three^[2]
Setting	Department of Respiratory and Critical Care Medicine, Peking University People's Hospital^[2]
Times cited	29^[2]

What remains unresolved about the variants

Would functional testing show whether the reported mutations alter gene expression or protein function?^[1]
How often do monoallelic LRBA variants contribute to a phenotype when they do not explain it alone?^[1]
What evidence would distinguish a disease-causing NFKB1 variant from a rare variant that is not responsible for the individual’s disease?^[3]

Questions about interpreting genetic variants

Does a TNFRSF13B variant by itself establish the cause of CVID?

No. The paper states that the TNFRSF13B variant in the reported patient was insufficient on its own to cause the phenotype, though it might contribute to CVID development.^{[1] [4]}

Sources

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1155/2018/3724630, Alternate LINK

Title: Common Variable Immunodeficiency With Genetic Defects Identified By Whole Exome Sequencing

Subject: General Immunology and Microbiology

Journal: BioMed Research International

Publisher: Hindawi Limited

Authors: Ran Li, Yali Zheng, Yuqian Li, Rongbao Zhang, Fang Wang, Donghong Yang, Yanliang Ma, Xinlin Mu, Zhaolong Cao, Zhancheng Gao

Published: 2018-09-30

Everything You Need To Know

What is Common Variable Immunodeficiency (CVID)?

Common Variable Immunodeficiency (CVID) is a primary immunodeficiency disorder (PID) characterized by varied symptoms and genetic causes. It often presents with recurrent respiratory infections but can also include autoimmune issues and an increased risk of malignancies. The heterogeneity of CVID highlights the importance of identifying the specific genetic defects to improve clinical management and provide a more precise understanding of the disease.

What is whole exome sequencing (WES), and how does it work?

Whole exome sequencing (WES) is a genetic testing method that examines the protein-coding regions of the genome, known as the exome. The process involves several key steps: exome capture, DNA sequencing using the Hiseq 4000 platform, data analysis including mapping the data to the human reference genome, and variant annotation using ANNOVAR software. This method is essential for pinpointing potential genetic defects, such as mutations, that might be missed by other tests. The ability to identify these defects allows for a move from managing symptoms to addressing the underlying molecular mechanisms of the disease.

Why is whole exome sequencing (WES) so important in diagnosing CVID?

In this context, whole exome sequencing (WES) is crucial for diagnosing CVID because it helps identify the specific genetic mutations that cause the disease. Due to the wide range of symptoms and genetic causes associated with CVID, pinpointing the genetic defects is essential for improving clinical management. By identifying these genetic defects, healthcare professionals can move beyond symptom management and develop more targeted treatments.

What were the key steps used in the study's genetic analysis?

The study employed several key steps, including exome capture using the Agilent SureSelect Human All Exon V6 kit, DNA sequencing using the Hiseq 4000 platform, data analysis with the Burrows-Wheeler Aligner (BWA), SAMtools, and Picard Tools, and variant annotation using ANNOVAR software. These steps collectively allowed researchers to identify the specific mutations driving the conditions of patients with CVID. Each step in the process contributes to a detailed genetic analysis that enhances the understanding of the molecular basis of CVID.

What are the implications of identifying specific genetic defects in CVID?

Identifying the specific genetic defects through methods like whole exome sequencing (WES) has significant implications for managing CVID. It allows for a more precise understanding of the disease, moving beyond symptom management to address the underlying molecular mechanisms. This approach leads to personalized treatment strategies tailored to each patient's unique genetic profile. This can improve the effectiveness of treatments, reduce side effects, and improve patient outcomes by providing more targeted therapies.